ArticleAmerican journal of translational research2025
Efficacy of percutaneous kyphoplasty in treating stage III Kümmell disease without neurological injury.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the safety and efficacy of percutaneous kyphoplasty (PKP) for Kümmell's disease with vertebral posterior wall defects but no neurological symptoms.
methodsThis retrospective study analyzed 79 patients with Kümmell disease, who were divided into an experimental group (with vertebral posterior wall rupture, n = 46) and a control group (with vertebral posterior wall intact, n = 33) based on imaging findings. Their vertebral height recovery, kyphosis correction, cement leakage rate, VAS scores, and postoperative changes were compared.
resultsAfter 10-26 months (avg. 18.9 months) of follow-up, both groups improved in vertebral height and Cobb angle post-operation. The control group had better postoperative vertebral height and Cobb angle recovery. At the last follow-up, the experimental group had more height and Cobb angle loss. VAS scores improved in both groups with no difference between them. There were 5 cement leakage cases in the experimental group and 3 in the control group, with no neurological symptoms (all P < 0.05).
conclusionPKP is safe and effective for stage III Kümmell's disease with or without posterior wall integrity. However, having intact posterior walls is better for maintaining vertebral height in long-term.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.